Sentences with phrase «from drug pricing»

The report eased concerns about the company's ability to withstand fallout from drug pricing pressures that have been a headwind for the industry.

Who benefits from drug prices or the ACA?

A solution to the problem — both from a drug price point of view and the ability to reimburse cancer drugs — does seem relatively elusive.

Not exact matches

Prices for roughly 300 generic drugs at least doubled from 2010 to 2015.

A 2012 report by the Kaiser Family Foundation calls the PBM assertions of Medicare savings «overstated» and says the reduced cost probably stemmed from incorrectly high predictions of prices and from brand drugs going generic.

He first gained notoriety back in September, after raising the price of a life - saving AIDS drug from $ 13.50 to $ 750 a pill.

And, as Barrett and Langreth write, drug makers often raise those list prices «to make up some of the lost revenue» from rebating.

One of Martin Shkreli's former companies has emerged from Chapter 11 bankruptcy and is pledging to ditch its notorious ex-chief's price hike plans for a rare disease drug.

In September, the pair sent a letter to Turing Pharmaceuticals CEO Martin Shkreli after he jacked up the price of Daraprim, a drug used to treat malaria and parasitic infections in patients with weakened immune systems, from $ 13.50 to $ 750 per pill.

Valeant, as the story unfolded, bought existing medications from other drug makers, as well as whole companies - then relentlessly hiked the prices of the drugs it acquired.

Lately pharma execs have been taking yet another volley of criticism over drug - pricing practices from Hillary Clinton and Marco Rubio — and plenty of others — without offering much in the way of a defense.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

If you haven't followed this story, you'll remember Shkreli from his fame two years ago, when his biotech firm, Turing Pharmaceuticals, acquired the patent to a drug used to treat malaria, cancer and aids, and jacked up the retail price by more than 5,000 percent.

Early Monday, Frazier resigned from the presidential council in protest, and Trump almost immediately took to Twitter, saying, «Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council, he will have more time to LOWER RIPOFF DRUG PRICES!»

That defensive position came under attack in 2015 as political rhetoric from both sides zeroed in on perceived unfair drug pricing.

Managed care could also stand to benefit from any change to drug pricing, making it a potentially attractive hedge against risks to biotech and pharmaceuticals.

The same outside adviser, who was unidentified in Tuesday's release, advised that a package of assistance programs to patients would: «force reporters to focus on the byzantine nature of drug pricing and health care and ensure the patient message gets out... specifically tie profits from Daraprim to the research and development of a new and more effective treatment for Daraprim patients.

Novum has steadily increased its price since that time, when it acquired the drug from Primus Pharmaceuticals, its previous owner.

A spokesperson for the drug company told the Financial Times that revenue from increased prices would go to investing in «schemes that ensured more patients could access the medicine.»

At the hearing, Dr. David Kimberlin, who specializes in pediatric infectious disease at the University of Alabama at Birmingham, spoke of a situation in September, around the time Daraprim's price went up after Turing bought the rights to the drug, in which he found barriers to getting the drug because the monthly cost for four tablets suddenly spiked to $ 3,000 from $ 54.

He has repeatedly called for allowing Medicare to directly negotiate drug prices, which would be bad for the industry's bottom line, and he has advocated legalizing the importation of medicines from nations where prices are lower.

Generic drug giant Mylan is cutting its financial outlook as it continues to face pressure from falling generic drug prices (a fate that similarly struck rival Teva Pharmaceuticals).

Turing Pharmaceuticals, which raised the price of a drug 5,500 % practically overnight says it will now lower its price following an intense backlash from the media, medical profession and the general public.

Speaking of Novartis — the company's experimental CTL019, which is expected to be the first approved drug in a revolutionary new cancer treatment space that turns the body's own immune cells into cancer - killers, is already facing some apprehension from doctors and patient groups who are worried about its eventual pricing.

More health plans and employers are signing up with pharmacy benefit managers like CVS Health (cvs) and Express Scripts (esrx), which control the list of drugs those insurance plans will cover, increasingly restricting patients from taking unreasonably high - priced drugs.

His company acquired the patent to a drug used to treat malaria, cancer, and AIDS, and increased its price from $ 13.50 to $ 750 a tablet — 5,455 percent.

Given its areas of specialization, Gilead wouldn't benefit as much from consolidation as, say, a generic - drug company would, but it still faces pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C drugs, which can cost more than $ 80,000 for a 12 - week course.

Clinton may still have had the right idea in wanting to prevent companies from price - gouging patients on life - saving drugs.

These firms receive rebates from drug manufacturers which may, according to some analyses, actually inflate drug prices.

And that's led to criticism from a consortium of critics which includes consumer advocacy groups and notorious drug price - hiker Martin Shkreli himself.

In the case of phenytoin sodium capsules, the U.K. price charged for 100 mg packs of the drug jumped from 2.83 pounds to 67.50 in 2012, before reducing to 54.00 from May 2014.

Herper homes in on a relatively new class of super-powerful (and super expensive) cholesterol - busting drugs called PCSK9 inhibitors (which were just shown to reduce death from any cause, and particularly heart - related conditions), and how patients with staggeringly high cholesterol who would benefit from the treatments had to wrangle with insurance companies that refused to cover them over their high prices.

We'd steered the conversation away from the drug - pricing issue.

But Trump's assertion that the federal government must start a bidding process for drugs in order to control prices and spending could very well invite similar criticisms from political opponents and the well - funded drug industry.

«If they don't acquiesce to the prices of the major drug - trafficking organizations, they're going to move on, and there's always somebody else that they can buy it from.»

Their appearance before Congress comes at an awkward and difficult time for the company, which is under fire from its shareholders and facing a number of ongoing government investigations into drug pricing and distribution, accounting and disclosures, and antitrust matters.

While some responders had particular axes to grind (it's true that U.S. drug prices are radically higher than elsewhere in the world, for instance, and maybe a gamma ray burst could destroy earth, but those aren't really things you can act on tomorrow), many more offered healthful reality checks that most of us could benefit from, including:

Novartis (nvs) chief Joe Jiminez has been touting a pricing model that incorporates drugs» real - world outcomes for years, stressing the importance of placing patients before profits; Regeneron (regn) head honcho Len Schliefer had some tough words for fellow panelists from Eli Lilly (lly) and Pfizer (pfe)(who argued that media reports about their own continued reliance on price increases to drive revenues is misleading) during Forbes» event.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Don't blame us for dramatic drug price hikes — that was the clear message from drugstore and pharmacy benefits manager CVS Health on Thursday.

Prices for the top 20 drugs prescribed to seniors rose by an average of 12 percent every year from 2012 to 2017.

A pricing survey from Consumer Reports revealed that prescription drug prices can differ by as much as 10 times between pharmacies, even within the same city.

Drugmakers have benefitted from the surge of opioid - related deaths in the U.S.; last year, Bloomberg reported that the drug's price had risen tenfold in recent years, with state and local governments shelling out to make the med more widely available.

Trump's move bore out a warning from Allergan CEO Brent Saunders late last year, as many in the industry assumed that the newly elected president would be kinder to pharma than his opponent Hillary Clinton, who'd laid out several proposals for controlling drug prices.

But you probably know Mr. Shkreli from his company Turing Pharmaceuticals's outrageous increasing of prices on a drug that helps people with compromised immune systems fight parasitic infections.

Roy Guharoy, chief pharmacy officer at 141 - hospital Ascension Health, said he didn't sign a contract from Valeant because it didn't promise to maintain lower prices on the drugs.

Valeant Pharmaceuticals, based in Bridgewater Township, N.J., bought two specialty heart drugs used in emergency treatment from Marathon Pharmaceuticals in 2015, and then dramatically increased each drug's price.

Investors have, on balance, concluded that the combination of a shift to very expansionary fiscal policy and major reductions in regulation in sectors ranging from energy to finance to drug pricing will raise demand and reflate the American economy.

Facing a backlash, representatives from the company stood before Congress in April and said they would work to cut prices for the drugs.

Rebates on all of Novo Nordisk's drugs in North America grew to about 50 percent of list prices in 2014, from around 35 percent in 2010, the company said.